Potent in vitro activity of sulbactam-durlobactam against NDM-producing Escherichia coli including cefiderocol and aztreonam-avibactam-resistant isolates
Clin Microbiol Infect. 2024 Oct 22:S1198-743X(24)00494-4.
doi: 10.1016/j.cmi.2024.10.012.
Online ahead of print.
1 Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland; Division of Intensive Care Unit, University Hospitals of Geneva, Geneva, Switzerland.
2 Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland.
3 Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland.
4 Department of Medicine, Medical and Molecular Microbiology Unit, University of Fribourg, Fribourg, Switzerland; Swiss National Reference Center for Emerging Antibiotic Resistance, Fribourg, Switzerland. Electronic address: laurent.poirel@unifr.ch.
5 ADMED Microbiologie La Chaux-de-Fonds, Switzerland.
6 Analytica Med. Laboratorien AG Zurich, Switzerland.
7 ANAMED SA Lausanne, Switzerland.
8 BACTOLAB AG Lausanne, Aarau, Switzerland.
9 Bakteriologisches Institut Olten AG Olten, Switzerland.
10 Bioanalytica AG Luzern, Switzerland.
11 CHUV Lausanne, Switzerland.
12 Clinique de La Source Lausanne CLS Lausanne, Switzerland.
13 Dianalabs Genève, Switzerland.
14 Dr Luc Salamin SA Sierre, Switzerland; Dr. Risch Ostschweiz AG Buchs, Switzerland.
15 Dr. Risch Liebefeld Liebefeld, Switzerland.
16 Dr. Risch Ticino SA Pregassona, Switzerland.
17 EOC-BELLINZONA Bellinzona, Switzerland.
18 Etablissements Hospitaliers Nord Vaudois (eHnv) Yverdon-Les-Bains, Switzerland.
19 Groupement Hospitalier de l'Ouest Lémanique S.A. (GHOL) Nyon, Switzerland.